1. Name Of The Medicinal Product
Asda Thrush Relief Cream
Lloydspharmacy Antifungal Skin Cream
Lloydspharmacy Thrush Femme Cream
Clotrimazole 1% cream BP
Boots Antifungal Cream
Tesco Antifungal Cream
Morrisons Thrush Relief Cream
Teva Thrush Relief 1% w/w Cream
2. Qualitative And Quantitative Composition
Clotrimazole B.P. 1% w/w
3. Pharmaceutical Form
Cream
4. Clinical Particulars
4.1 Therapeutic Indications
For the treatment of skin infections due to dermatophytes (e.g. trycophyton species), yeasts (e.g. candida species), moulds and other fungi. These include ringworm (tinea) infections, paronychia, pityriasis versicolor, erythrasma and intertrigo, as well as fungal nappy rash, candidal vulvitis and candidal balanitis.
4.2 Posology And Method Of Administration
Dosage:
Adult, children and elderly:
Apply to the affected area two or three times daily
Dermatophyte infections: treat for at least one month
Candida infections: treat for at least two weeks
Route of administration:
Directly applied to the affected area.
A physician should be consulted if symptoms do not improve within 7 days.
4.3 Contraindications
Known hypersensitivity to any of the components
4.4 Special Warnings And Precautions For Use
The cream contains cetyl alcohol and stearyl alcohol, which may cause local skin reaction (e.g. contact dermatitis).
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Clotrimazole Cream may cause damage to latex contraceptives. Consequently patient should be advised to use alternative precautions for at least five days after using this product.
4.6 Pregnancy And Lactation
Pregnancy
Data on a large number of exposed pregnancies indicate no adverse effects of Clotrimazole on pregnancy or on the health of the foetus/newborn child. To date, no other relevant epidemiological data are available.
Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife.
Breast-feeding
It is unknown whether clotrimazole is excreted in breast milk, so it should be given with caution to lactating mothers.
4.7 Effects On Ability To Drive And Use Machines
None known
4.8 Undesirable Effects
As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible.
Immune system disorders: allergic reaction (syncope, hypotension, dyspnoea, urticaria)
Skin and subcutaneous tissue disorders: blisters, discomfort/pain, oedema, irritation, peeling/exfoliation, pruritus, rash, stinging/burning
4.9 Overdose
In the event of accidental oral ingestion, gastric lavage is rarely required and should be considered only if a life-threatening amount of clotrimazole has been ingested within the preceding hour or if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). It should be carried out only if the airway can be protected adequately.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
ATC code: D01A C01
Clotrimazole is an imidazole derivative with a broad spectrum of antimycotic activity. It also exhibits activity against Trichomonas, staphylococci, streptococci and Bacteroides. It has no effect on lactobacilli.
Mechanism of action
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the cytoplasmic membrane.
Pharmacodynamic effects
Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.
The mode of action of clotrimazole is fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. In-vitro activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive.
Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.
5.2 Pharmacokinetic Properties
Pharmacokinetic investigations after dermal application have shown that clotrimazole is minimally absorbed from the intact or inflamed skin into the human blood circulation. The resulting peak serum concentrations of clotrimazole were below the detection limit of 0.001 mcg/ml, suggesting that clotrimazole applied topically is unlikely to lead to measurable systemic effects or side effects.
5.3 Preclinical Safety Data
There are no preclinical data of reference to the prescriber which are additional to the information included in other sections of the SPC.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Sorbitan stearate
Polysorbate 60
Cetyl Esters Wax
Stearyl Alcohol
Cetyl Alcohol
2-Octyldodecanol
Benzyl Alcohol
Purified Water
6.2 Incompatibilities
None known
6.3 Shelf Life
36 months
6.4 Special Precautions For Storage
None
6.5 Nature And Contents Of Container
Aluminium tube with polypropylene screw-on cap containing 20/30/50g of cream.
6.6 Special Precautions For Disposal And Other Handling
None
7. Marketing Authorisation Holder
Teva UK Limited
Brampton Road
Hampden Park
Eastbourne
East Sussex
BN22 9AG
8. Marketing Authorisation Number(S)
PL 00289/1490
9. Date Of First Authorisation/Renewal Of The Authorisation
27 January 1998 / 08 April 2003
10. Date Of Revision Of The Text
06/06/2011
No comments:
Post a Comment